Margareta H.
- Country
- Sweden
- Department
- VO hematologi, onklologi och strålningsfysik
Research Overview
- Phase III Trial on Disease-Free Survival in Resected Pancreatic Ductal Adenocarcinoma Using Oxaliplatin or Gemcitabine-Based Chemotherapy Allocation by Transcriptomic Signature
- Efficacy and Safety of Zanidatamab with Cisplatin and Gemcitabine in Advanced HER2-Positive Biliary Tract Cancer: A Randomized Controlled Trial
- Phase 2/3 Randomized Study of BMS-986504 with Nab-Paclitaxel and Gemcitabine vs. Placebo in Metastatic Pancreatic Ductal Adenocarcinoma with Homozygous MTAP Deletion
Data & Insights
Has run more than one trial at 35 of 144 partner sites.
Specializations
Gastrointestinal Oncology
This investigator specializes in treating advanced biliary tract cancers and pancreatic ductal adenocarcinoma, with particular emphasis on innovative therapeutic approaches for patients with resected tumors.
- Biliary Tract Cancer Management
- Pancreatic Cancer Treatment
- Post-surgical Cancer Care
The investigator focuses on personalized treatment strategies incorporating targeted therapies and chemotherapy combinations.
Targeted Therapy
Expertise in HER2-positive cancer treatments and the application of targeted therapeutic agents, particularly in gastrointestinal malignancies.
- HER2-Targeted Treatments
- Immunotherapy Integration
- Combination Therapy Approaches
The investigator explores novel combinations of targeted agents with standard chemotherapy regimens.
Precision Medicine
Specializes in biomarker-driven treatment selection and the development of personalized therapeutic strategies based on genetic markers.
- Treatment-Specific Signatures
- Genetic Marker Analysis
- Personalized Chemotherapy Selection
The investigator evaluates treatment outcomes based on molecular profiling and genetic characteristics.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.